Institutional Review Board, Hospital for Special Surgery
November 09, 2022
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
The purpose of this study is to understand the function of this the PKRG1 gene and its role in systemic lupus erythematosus (SLE). Your biological samples and corresponding data provided by you and gathered from your medical record will be used for the purpose of this study.
A total of 60 subjects will participate in this study at HSS.
All patients will be required to participate in 1 baseline visit over the next 12 months.